26 July 2017 Catherine Barker, Arin Dutta, Kate Klein

Slides:



Advertisements
Similar presentations
Resource requirements for reaching the treatment goals under PEPFAR XV International AIDS Conference Bangkok July 15, 2004 Owen Smith, Abt Associates Inc.
Advertisements

Group III: Demand Forecasting
Contribution of Economics to Operational Research for Evaluation of Scaling Up Access to HIV Care & Treatment in Developing Countries Presentation by Pr.
Absorption, Retention and Empowerment
Long-term Projections of the Cost of Treatment Under Various Scenarios – Opportunities for Efficiency and Effectiveness? Arin Dutta, Cathy Barker, and.
EMTCT Tanzania Experience 6 th Joint Biennial HIV & AIDS Sector Review Dr MD Kajoka PMTCT Coordinator.
Fast-track to ending AIDS in Zimbabwe: opportunities
Pediatric HIV Care & Treatment in Uganda A Five-Day Training Course For Health Professionals.
Antiretroviral Treatment (ART) & Human resources Wim Van Damme Department of Public Health ITM, 17 October 2006.
2013 WHO Consolidated ARV Guidelines Summary of Major Recommendations and Estimated Impact GSG Briefing July 19, 2013 Gottfried Hirnschall, Director HIV.
High-impact interventions. Number of people living with HIV who were not receiving antiretroviral therapy, 2014 and 2015 Source: UNAIDS estimates, 2014.
Efficiency, Effectiveness, and Financial Sustainability: The Importance of Country Ownership Dr Bernhard Schwartländer UNAIDS.
Fast-Tracking Treatment to End AIDS ICASA Ambassador Deborah Birx, MD U.S. Global AIDS Coordinator November 30, 2015.
Virginia Macdonald, HIV Department World Health Organization
Scaling up Access to HIV treatment What can we learn for NCDs?
Lynne Wilkinson IAS.
Contents - HIV global slides
Dr. Tsitsi Apollo Ministry of Health and Child Care, Zimbabwe
Differentiated Monitoring & Evaluation
How differentiated care supports “Tx all” and Dr
Demanding a high impact HIV response: civil society advocacy and the President’s Emergency Plan for Aids Relief (PEPFAR) Dorothy Namutamba International.
20:20 Vision Making new and old money work better
Contents Global impact 2.Service cascade 3. Policies and WHO support.
TITLE Differentiated Care for People who inject Drugs, Men who have sex with men, Sex workers, Transgender people, Prisoners and other people living in.
Number of people receiving antiretroviral therapy in
HIV and AIDS The management of HIV and AIDS is an ongoing challenge for Anglo companies operating in countries with a high burden of HIV disease Strategy.
Differentiated Service Delivery: Innovating for Impact
“Treatment for all pregnant women:
Facilitating development and adaptation of the right tools
Abstract #: WEAD0203 Estimating the size of the pediatric ARV market in 27 low- and middle-income countries (LMICs) through 2025 as PMTCT initiatives continue.
Zimbabwe’s shift towards treat all: national country context
2017 Key Considerations for adolescents and children & Key populations
Expanding ARV treatment in developing countries: Issues and Prospects
First roll out of universal access to antiretroviral therapy under routine program conditions in rural Swaziland. Authors: Bernhard Kerschberger (1), Sikhathele.
Pakistan Last updated: July 2015.
World Health Organization
Madisa Mine National Health Laboratory Gaborone, BOTSWANA
Country policies to enable Differentiated Care: Four country examples
Utilizing research as an opportunity to strengthen
The Last Mile to EMTCT: Are we there yet?
Implementation of the Appointment Spacing Model of Differentiated Service Delivery in Ethiopia: Successes and Challenges Tamrat Assefa1, Zenebe Melaku1,
WHO HIV update July 2018 Global epidemic Global progress and cascade
World Health Organization
International AIDS Economics Network (IAEN) Conference
HIV Trends Among Youth Ages in 23 Countries
Dr. Samson Kironde USAID HRH2030 Program July 23, 2018
Thokozani Kalua MBBS MSc Malawi Ministry of Health
The Cost of Differentiated Service Delivery: A Systematic Review
Contents - HIV global slides
Mapping the Scale-Up of DSD: A 13-Country Health Facility Survey
Jepkoech Kottutt1, Emilia D. Rivadeneira2, Susan Hrapcak2
Wafaa El-Sadr, MD, MPH, MPA ICAP at Columbia University
DIRECÇÃO PROVINCIAL DE SAÚDE TETE
Forecasting the Cost of Financing ART in Sub-Saharan Africa under Differential Funding Scenarios Tahvi Frank and Austin Carter July 25, 2018.
China 2010 UNGASS Country Progress Report
July 21, 2016 Potential Domestic Source Financing for Scaled Up Antiretroviral Therapy in 97 Countries, 2016–2020 Arin Dutta, Catherine Barker, and Ashley.
Access and Rights Now Reengaging Adolescents in Treatment and Care.
From toward HIV Elimination with Boosted-Integrated Active HIV Case Management (B-IACM) in Cambodia Dr. Penh Sun LY, Director, NCHADS Presented.
Towards the last 90% of the 90:90:90 strategy: A review of viral suppression rates in a HIV program in Central and Eastern Kenya Dr Moses Kitheka,
Financing South Africa’s HIV Response
Contents - HIV global slides
Introduction to poster session and discussion
Contents - HIV global slides
Contents Global impact 2.Service cascade 3. Policies and WHO support.
Multi-disease diagnostic integration
CQUIN Call to Action Peter Preko MB, ChB Project Director, CQUIN
Start Free, Stay Free, AIDS Free
Update on global progress in ART
For a healthy Zambia.
Introduction and current status of viral load access
Presentation transcript:

26 July 2017 Catherine Barker, Arin Dutta, Kate Klein Can differentiated care models solve the crisis in HIV treatment financing? Analysis of prospects for 38 countries in sub-Saharan Africa 26 July 2017 Catherine Barker, Arin Dutta, Kate Klein

Facility-level ART funding gap1 Countries face financial and health system constraints to meeting 90-90-90 Facility-level ART funding gap1 WHO projects a net shortage of 15 million health workers by 20302 Sources: Dutta A, Barker C, Kallarakal A (2015) The HIV Treatment Gap: Estimates of the Financial Resources Needed versus Available for Scale-Up of Antiretroviral Therapy in 97 Countries from 2015 to 2020. PLOS Medicine 12(11): e1001907. https://doi.org/10.1371/journal.pmed.1001907 Liu JX, Goryakin Y, Maeda A, Bruckner T, Scheffler R. Global health workforce labor market projections for 2030. Human resources for health. 2017 Feb 3;15(1):11. Palladium Corporate Presentation

Are differentiated care models (DCMs) a potential solution? “Differentiated care is a client-centered approach that simplifies and adapts HIV services across the cascade to reflect the preferences and expectations of various groups of people living with HIV (PLHIV) while reducing unnecessary burdens on the health system.” -International AIDS Society Beatrice Tierney Health Clinic in Bupoto, Uganda Jhpiego. Community workers in Mozambique Facility-level ART management Community-level ART management Evidence from: South Africa Zimbabwe Uganda Swaziland Zambia Frequency of visits and lab monitoring depend on patient characteristics and behavior, including response to treatment Palladium Corporate Presentation

Laboratory monitoring Frontline health workers Our analysis: Estimating facility-level cost and health-worker savings from DCMs Research question: What are the potential health system efficiency gains in terms of reduced facility-level costs and number of health workers needed for ART from implementing DCMs in 38 countries from 2016 to 2020? Stylized DCMs: Two criteria: Age and stability Four criteria: Age, stability, key vs. general population, rural vs. urban population Costs included: Countries included: ARVs Laboratory monitoring Frontline health workers Facility overhead Community ART support (DCMs only) Palladium Corporate Presentation

Our analysis: Stylized DCM scenarios Frequency per year or percentage receiving community-based support Model 1: Undiffer-entiated care Model 3: Four-criteria DCM (differentiation by age, stability, key population, and urban/rural) Model 2: Two-criteria - Age and stability DCM Key popu-lations^ Urban# Rural# Children 0-9 Adolescents 10-19 Adults 20+ New Stable~ Unstable Clinical visits 6 4 5 3 2 4 to 6 2 to 6 Refill visits 3 to 7 1 to 5 Diagnostic management* Viral load 1 1 to 2 CD4 Clinical chemistry 1* Hematology 1** Coverage of community-based ART support or home visits 0% 100% Lower cost Higher cost ~Stable patients are those receiving ART for at least one year with no adverse drug reactions, no current opportunistic infections or pregnancy, a good understanding of lifelong adherence, and evidence of treatment success. We assumed all patients who are on treatment for at least one year and virally suppressed are stable. Country- or regional-specific data on viral suppression came from peer-reviewed literature. *Clinical chemistry tests are for those on TDF-containing regimens. **Hematology tests are for those on AZT-containing regimens. ^Key populations for this analysis are defined as men who have sex with men, sex workers, and people who inject drugs. For our analysis, key populations are a subset of the adult population only. New and stable key populations have 4 visits per year, unstable key populations have 6. #The entire population can be segmented in urban vs. rural. Due to closer proximity to facilities in urban areas, the model assumes additional refill visits and fewer community ART support meetings for those residing in urban areas compared with rural areas. Palladium Corporate Presentation

Full-time equivalent (FTE) health workers Methods: Estimating numbers on treatment, unit costs, and health workers needed Numbers on treatment Description of methods Estimated number of people living with HIV by age group (accounting for uncertainty) Assumed linear scale-up in coverage to 81% by 2020 or 2025, depending on baseline levels Further segmented numbers on ART by stability, key vs. general population, and urban vs. rural population Data sources Official country AIM files (2016) AIDSinfo PEPFAR COPs Peer-reviewed literature Unit costs Estimated baseline facility and community level ART costs Assumed declines in costs for ARVs and lab commodities over time Accounted for uncertainty in unit costs Global Price Reporting Mechanism (GPRM) database Peer-reviewed literature Full-time equivalent (FTE) health workers Estimated the number of FTEs based on the number of patient visits per year and the amount of time health workers spend per visit Peer-reviewed literature Palladium Corporate Presentation

Results: Number of people on ART Numbers on treatment in 2020 19.0 17.5 16.1 14.7 13.5 Note: Whiskers denote 95% confidence interval. Note: Key vs. general population segmentation for adults only. Palladium Corporate Presentation

Results: ART costs across all 38 countries Total: $23.3 billion Key takeaways: 17.5% (US$4.1 billion) and 16.8% (US$3.9 billion) could be saved from 2016 to 2020 from implementing the two- criteria DCM and four- criteria DCM, respectively. Community health costs would need to average US$125 per person to eliminate any cost savings from DCMs. Total: $19.2 billion Total: $19.4 billion Palladium Corporate Presentation

Results: FTE health workers required by scenario Key takeaways: DCM scenarios require fewer health worker FTEs for ART, meaning health workers may be able to see additional patients or perform other tasks. In 2020, about 46% fewer FTE health workers are needed under the DCM scenarios compared with the undifferentiated care scenario. Palladium Corporate Presentation

Estimated cost savings from implementing DCMs from 2016 to 2020. DCMs may allow more people on treatment with the same resource envelope Limitations: Lack of data on community-level ART support costs. Exclusion of above- site costs, including start-up costs for implementing DCMs. Examined cost savings only from the health system funders’ perspective. US$3.9 to US$4.1 billion Estimated cost savings from implementing DCMs from 2016 to 2020. Reduction in the financing gap for facility-based ART services under DCMs, even after accounting for additional community-level ART support costs. 32% to 36% 46% Savings in health worker time in 2020 from implementing DCMs. Palladium Corporate Presentation

Realizing efficiency gains will depend on how countries implement DCMs After DCM, can health workers be managed such that any freed-up time is fully utilizable? Multi-month scripting reduces patient refill visits. DCM may also reduce clinical visits  This frees up facility-based staff time  If staff are assigned only to ART site/CCT then they cannot be easily shifted to other needs X  Facility owners (government, NGOs) may need to make a decision Option: manage more ART patients at same site to use freed capacity?  But what if decentralizing ART? Will there be policies and plans in place to guide roll-out of DCMs, including re-training of health workers? What will this cost? What if some patients do not want to visit the clinic less often or be managed at the community level? Patients Will health information systems be responsive to DCMs? Health workers Even if efficiency gains from DCMs cannot be fully realized, DCMs may be worthwhile due to reduced cost and effort for most patients, and pilot programs showing DCMs may improve ART outcomes Palladium Corporate Presentation